首页> Annals of the rheumatic diseases> Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study.

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study.

导出 OA

翻译打印收藏纠错

第一作者： Mark C,Genovese

第一单位： Division of Immunology and Rheumatology, Stanford University Medical Center, Stanford, USA.

作者： Mark C,Genovese ^[1] ; Roy,Fleischmann ^[2] ; Daniel,Furst ^[3] ; Namieta,Janssen ^[4] ; John,Carter ^[5] ; Bhaskar,Dasgupta ^[6] ; Judy,Bryson ^[7] ; Benjamin,Duncan ^[7] ; Wei,Zhu ^[7] ; Costantino,Pitzalis ^[8] ; Patrick,Durez ^[9] ; Kosmas,Kretsos ^[10]

作者单位： Division of Immunology and Rheumatology, Stanford University Medical Center, Stanford, USA. ^[1] Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, USA. ^[2] Department of Medicine, UCLA, Los Angeles, California, USA. ^[3] Houston Institute for Clinical Research, Houston, USA. ^[4] Division of Rheumatology, University of South Florida Health, Tampa, Florida, USA. ^[5] Department of Rheumatology, Southend University Hospital, Westcliff-on-Sea, UK. ^[6] UCB Pharma, Raleigh, USA. ^[7] William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. ^[8] Service et Pôle de Rhumatologie, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium. ^[9] UCB Pharma, Slough, UK. ^[10]

关键词 Autoimmune Diseases DMARDs (biologic)Disease Activity Rheumatoid Arthritis